Disease Awareness Program Excellence: Interview Narratives and Best Practices

STUDY OVERVIEW

Disease state awareness campaigns have long been used by the pharmaceutical industry to disseminate unbranded information to key external stakeholders, such as physicians and patients. These programs also set the table for future marketing efforts at product launch and post-launch. Today, more than ever, understanding how to utilize these programs is critical.

Best Practices, LLC conducted a primary research study that looked at issues such as when are companies first using disease awareness programs and when should you invest the most resources in disease awareness campaigns?

The study provides highlights from interviews, spotlighting effective practices and challenges participants have faced regarding disease awareness programs. In addition, this document presents best practices and pitfalls that participants have learned from past disease awareness campaigns.


KEY TOPICS

• Narratives from Interviews
• Best Practices and Pitfalls
  

• Disease Awareness to Prepare For Launch
• Utilizing Clinical Trial Results for Disease Awareness
• European Regulatory Approaches
• Finding Success in Crowded Therapeutic Areas
• Developing Relationships with Patient Advocacy Groups
• Conference Benefits

• Most Impactful Awareness Activities are Personal Interactions with Physicians/TLs: Interviewed disease awareness veterans spoke of the importance of personal interactions with prescribers and thought leaders. "Without a doubt, what our development and medical colleagues are able to do in a conference setting is so credible," said one senior director.

• Sixteen leaders at 16 leading pharmaceutical and biotech organizations participated in this study. In addition, one global communications firm representing a biopharma client also participated.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Public Relations; Health Care; Biopharmaceutical


Companies Profiled:
Bayer; Abbvie; Genzyme; Adamas Pharmaceuticals; AstraZeneca; Biogen; Novartis; Eli Lilly; FleishmanHillard; Fresenius Medical Care AG & Co. KGaA; ZS Pharma; Indivior; Merck; Catalyst Pharmaceuticals; Prometheus Therapeutics & Diagnostics; Tokai Pharmaceuticals; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.